| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Departments of Internal Medicine (S.F., E.A.P., A.C., F.B., L.S.) and Endocrinology (B.B., N.P., G.L.) of the University Federico II, and Department of Endocrinology (C.C.) of the Second University, Naples, Italy
Address all correspondence and requests for reprints to: Luigi Saccà, M.D., Department of Internal Medicine, via Pansini, 5, 80131 Naples, Italy.
 |
Abstract |
|---|
 Top Abstract IntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Twenty-six patients (mean age, 36 ± 12 yr) were evaluated by Doppler-echocardiography, whereas a subgroup of 10 patients, randomly selected, were reevaluated after 6 months of L-T4 substitutive therapy (mean dose, 68 µg daily). Thirty subjects (matched for age, sex, and body surface area) served as controls.
Mean plasma TSH was significantly higher in patients (P < 0.001), whereas mean serum free T4 and free T3 concentrations, although in the normal range, were significantly lower (P < 0.001 and P < 0.005, respectively). Blood pressure and heart rate did not differ from control values. Echocardiogram examination showed no abnormalities of the left ventricular morphology and a slight, but not significant, reduction in the systolic function in the patient group. In contrast, Doppler-derived indices of diastolic function showed significant prolongation of the isovolumic relaxation time (94 ± 13 vs. 84 ± 8 msec; P < 0.001), increased A wave (55 ± 13 vs. 48 ± 9 cm/sec; P < 0.05), and reduced early diastolic mitral flow velocity/late diastolic mitral flow velocity ratio (1.4 ± 0.3 vs. 1.7 ± 0.3; P < 0.001). In the subgroup of 10 patients, thyroid hormone profile was normalized by 6 months of L-T4 substitutive therapy, whereas no changes were observed in the left ventricular morphology. Systolic function was significantly enhanced, as compared with pretreatment values (P < 0.01) but did not differ from control values. Also, systemic vascular resistance was significantly decreased by L-T4 replacement therapy. Assessment of diastolic function showed significant shortening of isovolumic relaxation time (77 ± 15 vs. 91 ± 8; P < 0.05), reduction of A wave (51 ± 13 vs. 60 ± 12; P < 0.01), and increase of early diastolic mitral flow velocity/late diastolic mitral flow velocity ratio (1.7 ± 0.4 vs. 1.3 ± 0.3; P < 0.001). These indices, however, were comparable with those of control subjects.
These findings indicate that subclinical hypothyroidism affects diastolic function and that this abnormality may be reversed by L-T4 substitutive therapy.
|
Introduction |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
The clinical presentation of SHypo is nonspecific, and the symptoms are usually subtle, as compared with those of overt hypothyroidism, probably in relation to the intensity and the duration of thyroid hormone deficiency and the age of the patients.
The decision to treat the patients affected by SHypo with substitutive L-T4 therapy remains controversial (1, 2, 3) and mainly dependent on the physician’s attitude (to consider the disease as a mild form of tissue hypothyroidism or as a compensate state, in which the increase of TSH is required to maintain normal circulating thyroid hormone concentrations). Indeed, reports on the efficacy of replacement therapy with levothyroxine (L-T4) on the lipid abnormalities in the patients with SHypo have shown conflicting results (4, 5, 6, 7, 8, 9, 10). However, although it is difficult to establish a cutoff for TSH values that clearly indicates the need to institute a substitutive therapy with L-T4, the treatment is generally recommended in the presence of a serum TSH level of 10 mU/L or more (2, 11, 12). When the TSH level is less than 10 mU/L, the treatment may be indicated in relation to the presence of goiter or antithyroid antibodies to prevent the onset of overt hypothyroidism more than to tissue assessment of thyroid hormone deficiency (1).
Considering the high prevalence of SHypo and the well-established cardiac consequences of altered thyroid status, in the present study, we investigated whether SHypo causes cardiovascular abnormalities. To this aim, we assessed cardiac morphology and function, using noninvasive methods, in patients with SHypo before and after L-T4 substitutive therapy.
|
Subjects and Methods |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
SHypo was diagnosed on the basis of TSH values above normal (see
Table 1
), associated with a supranormal
response to TRH (
TSH above 30 mU/L), and FT3 and
FT4 in the lower limit of the normal range. Only the
patients with stable TSH and thyroid hormone levels for at least 6
months before the enrollment and with a positive test for serum
antithyroid peroxidase antibodies were included in the study. TSH and
thyroid hormone levels were considered stable if their variations were
lower than 20% in three consecutive evaluations performed in the 6
months before study. Patients and normal volunteers had a sedentary
life-style, none of them had a history of cardiovascular disease, and
all were in sinus rhythm.
|
All subjects gave informed consent before participating in the study, and the protocol was approved by the Ethics Committee of the University of Naples Federico II.
Assessment of thyroid status
Evaluation of plasma TSH levels was performed by an ultrasensitive immunoradiometric assay (Bouty, Milan, Italy) with a detection limit of 0.05 mU/L. The intra- and interassay variations were 3.1% and 3.8% at 0.25–50 mU/L. Serum FT4 and FT3 were measured using the Lisophase Kits (Bouty). The intra- and interassay variations and sensitivities were 2.9%, 4.7%, and 0.8 pmol/L for FT3, respectively, and 4.1%, 5.9%, and 1.0 pmol/L for FT4.
Doppler-echocardiography
Complete mono- and two-dimensional, and Doppler-echocardiographic analysis was performed by an ultrasound mechanical system equipped with a 3.5-MHz transducer (Apogee CX, Interspec, Inc., Ambler, PA), as previously described (13, 14). The examinations were performed by the same operator for all participants in the study. The investigator reading the echoes was blinded as to whether the recordings he was interpreting were of hypothyroid or normal subjects.
The parameters of systolic and diastolic function, derived by echocardiography and by Doppler examination, were assessed as previously reported (14, 15). Stroke volume was obtained using the method of Teichholz et al. (16). Cardiac output (CO) was measured as the product of stroke volume and heart rate. Systemic vascular resistance (SVR) was calculated as follows: SVR = [(mPAO-mPRA)/CO] x 80, where mPRA is the mean right atrial pressure, considered equal to zero mm Hg in each subject, and mPAO is the mean aortic pressure, derived by cuff-sphygmomanometer, as diastolic blood pressure + 1/3(systolic-diastolic blood pressure) (17). Furthermore, aortic peak flow velocity and mean aortic acceleration were obtained by the recording of the aortic flow velocimetry. In particular, mean aortic acceleration was obtained by dividing the peak flow velocity by the acceleration time (18).
Statistical analysis
All data in the text and tables are reported as the mean ± SD. Comparisons among control subjects and subclinical hypothyroid patients were performed by the two-tailed Student’s t test for unpaired data, whereas comparisons among the subgroup of 10 subclinical hypothyroid patients, before and 6 months after L-T4 treatment, were performed using the two-tailed Student’s t test for paired data. A P value less than 0.05 was considered as significant.
|
Results |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
. Patients and normal controls were well matched for
age, sex, and body surface area. Both heart rate and blood pressure
were comparable in the two groups. As expected, TSH levels were
significantly higher in patients than in controls. FT3 and
FT4 levels, although in the normal range, were
significantly lower in the patients than in control subjects.
As summarized in Table 2, no
abnormalities were found in LV morphology and mass in the
patients with SHypo.
|
displays
Doppler-echocardiographic resting indices of LV systolic and diastolic
function. No clear evidence of systolic dysfunction was found in the
patient group. The only abnormality was a significant, although mild,
decrease in the mean aortic acceleration.
|
) and significant reduction of the early diastolic mitral flow
velocity/late diastolic mitral flow velocity (E/A) ratio, mainly
accounted for by increased A-wave of mitral flow velocity.
|
As summarized in Tables 4 and 5,
L-T4 substitutive therapy did not induce
significant changes in LV morphology. In contrast, Doppler indices of
diastolic function were normalized by L-T4
therapy, whereas systolic function improved. In particular, the
isovolumic relaxation time shortened significantly to values comparable
with those of normal subjects (Fig. 1), and the E/A ratio increased
significantly. Fractional shortening, mean velocity of circumferential
fiber shortening, and mean aortic acceleration were all enhanced by
L-T4 therapy, although they were still in the
normal range. Moreover, CO increased slightly, but not significantly,
whereas SVR was reduced by L-T4 treatment,
although it was not significantly different from the mean value of the
control subjects.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Cardiac function has been previously evaluated in patients with SHypo, by systolic time intervals, with conflicting results (19, 20, 21, 22, 23, 24, 25). Some authors reported prolonged systolic time intervals in SHypo (19, 20, 21), which improved after L-T4 therapy, particularly in those patients with more marked basal abnormalities (20). In contrast, Tseng et al. found that the isovolumic contraction time, the preejection period, and the ratio of preejection period to LV ejection time were normal in patients with SHypo (25), as assessed by simultaneous recording of aortic and mitral flow velocities.
Arem et al., using Doppler echocardiography at rest and during exercise in eight patients with SHypo, found normal cardiac structure and function, and mild prolongation of the preejection period during exercise and slightly reduced LV diastolic dimensions at rest (26).
Bell et al. showed, by radionuclide ventriculography, that patients with SHypo have normal ejection fraction at rest, with a small (but significant) increase in LV ejection fraction during maximal exercise after L-T4 therapy (27). Forfar et al. also reported a blunted increase in ejection fraction during exercise, with a clear improvement in this parameter after L-T4 replacement therapy (28). Moreover, Foldes et al. found a lower ejection fraction, both at rest and during physical exercise, in patients with SHypo, as compared with normal subjects (29).
The discrepant results reported in previous studies of cardiac involvement in SHypo might be, in part, related to the different patient selection (age, inclusion of patients with previous hyperthyroidism, evaluation of patients with acute or unstable SHypo) and to the different diagnostic criteria (too-large range of TSH levels).
In the present study, we performed a strict selection of patients with stable SHypo, excluding patients with confounding factors particularly affecting the cardiovascular system. The impaired diastolic function in this group of patients suggests that SHypo is a condition of minimal tissue hypothyroidism rather than a compensated state. If this is the case, the patients with SHypo should all be considered as potential candidates for therapy with L-T4.
The idea that SHypo should be treated is also supported by a recent study from Perk et al., who found greater progression of left coronary angiographic lesions in hypothyroid patients with TSH levels in the range seen in SHypo, compared with patients whose TSH levels were assiduously maintained in the normal range (30).
An impairment of diastolic function is a common finding in many cardiac diseases, and it often precedes and causes systolic dysfunction (31). It has been documented that 30–40% of heart failure syndromes are secondary to impaired diastolic function (31). Therefore, the diastolic dysfunction observed in the current study could be the prelude to more serious limitations of cardiac function and physical performance. In this regard, our finding may be causally related to the blunted increase of LV ejection fraction during exercise observed in patients with SHypo (27, 28).
There is a seeming discrepancy between the results of the present study and our previous findings in subclinical hyperthyroidism (14). Specifically, both subclinical hyperthyroidism and hypothyroidism patients show similar diastolic abnormalities despite opposite hormonal patterns. However, subclinical hyperthyroidism is associated with mild LV hypertrophy, whose well-known deleterious consequences on diastolic function (31) may prevail over the enhanced relaxation induced by thyroid hormone excess (32). On the other hand, SHypo may impair directly diastolic function by reducing sarcoplasmatic calcium ATPase activity, with consequent impairment of ventricular diastolic function (33).
Among the indices of systolic function, only mean aortic acceleration was significantly reduced in the group of patients with SHypo. Therefore, this index seems to be the most susceptible to variations in thyroid hormone levels. Furthermore, in the groups of patients with SHypo treated with replacement L-T4 therapy, SVR was significantly reduced, which confirms a direct vasodilatory effect of thyroid hormone (34).
Doppler-echocardiography represents a simple and reliable method for the evaluation of morphology and function in patients with SHypo. An additional advantage is its easy repeatability and, therefore, it could be used to serially evaluate the adequacy and efficacy of L-T4 dose. To support this concept, in the subgroup of patients treated with substitutive doses of L-T4, the echo-Doppler evaluation performed after 6 months demonstrated an improvement of cardiac function.
In conclusion, the results of this study show that diastolic function is impaired in patients with stable SHypo. This abnormality is reversible after 6 months of substitutive L-T4 therapy. Doppler-echocardiography may be considered a reliable method for a cross-sectional and longitudinal assessment of left ventricular diastolic function in patients with SHypo.
Received October 26, 1998.
Revised February 3, 1999.
Accepted February 26, 1999.
|
References |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  Y. J. Park, J. W. Yoon, K. I. Kim, Y. J. Lee, K. W. Kim, S. H. Choi, S. Lim, D. J. Choi, K.-H. Park, J. H. Choh, et al. Subclinical Hypothyroidism Might Increase the Risk of Transient Atrial Fibrillation After Coronary Artery Bypass Grafting. Ann. Thorac. Surg., June 1, 2009; 87(6): 1846 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Rodondi, D. C. Bauer, A. R. Cappola, J. Cornuz, J. Robbins, L. P. Fried, P. W. Ladenson, E. Vittinghoff, J. S. Gottdiener, and A. B. Newman Subclinical Thyroid Dysfunction, Cardiac Function, and the Risk of Heart Failure: The Cardiovascular Health Study J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1152 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Salerno, U. Oliviero, T. Lettiero, V. Guardasole, D. M. Mattiacci, L. Saldamarco, D. Capalbo, A. Lucariello, L. Sacca, and A. Cittadini Long-Term Cardiovascular Effects of Levothyroxine Therapy in Young Adults with Congenital Hypothyroidism J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2486 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pingitore, E. Galli, A. Barison, A. Iervasi, M. Scarlattini, D. Nucci, A. L'Abbate, R. Mariotti, and G. Iervasi Acute Effects of Triiodothyronine (T3) Replacement Therapy in Patients with Chronic Heart Failure and Low-T3 Syndrome: A Randomized, Placebo-Controlled Study J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1351 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Biondi and D. S. Cooper The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev., February 1, 2008; 29(1): 76 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Iqbal, H. Schirmer, P. Lunde, Y. Figenschau, K. Rasmussen, and R. Jorde Thyroid Stimulating Hormone and Left Ventricular Function J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3504 - 3510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Iervasi, S. Molinaro, P. Landi, M. C. Taddei, E. Galli, F. Mariani, A. L'Abbate, and A. Pingitore Association Between Increased Mortality and Mild Thyroid Dysfunction in Cardiac Patients Arch Intern Med, July 23, 2007; 167(14): 1526 - 1532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Turhan, C. Tulunay, M. Ozduman Cin, A. Gursoy, M. Kilickap, I. Dincer, B. Candemir, S. Gullu, and C. Erol Effects of Thyroxine Therapy on Right Ventricular Systolic and Diastolic Function in Patients with Subclinical Hypothyroidism: A Study by Pulsed Wave Tissue Doppler Imaging J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3490 - 3493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-L. Fabrizio, D. B. Vitantonio, T. Enrica, D. C. Andrea, M. Fabio, A. Lucia, P. Caterina, C. Nadia, D. D. M. Grazia, N. Carmela, et al. Early textural and functional alterations of left ventricular myocardium in mild hypothyroidism. Eur. J. Endocrinol., July 1, 2006; 155(1): 3 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Cappola, L. P. Fried, A. M. Arnold, M. D. Danese, L. H. Kuller, G. L. Burke, R. P. Tracy, and P. W. Ladenson Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults JAMA, March 1, 2006; 295(9): 1033 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Rodondi, A. B. Newman, E. Vittinghoff, N. de Rekeneire, S. Satterfield, T. B. Harris, and D. C. Bauer Subclinical Hypothyroidism and the Risk of Heart Failure, Other Cardiovascular Events, and Death Arch Intern Med, November 28, 2005; 165(21): 2460 - 2466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gumieniak, S. Hurwitz, T. S. Perlstein, U. C. Ngumezi, P. N. Hopkins, X. Jeunemaitre, and G. H. Williams Aggregation of High-Normal Thyroid-Stimulating Hormone in Hypertensive Families J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 5985 - 5990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wartofsky and R. A Dickey The Evidence for a Narrower Thyrotropin Reference Range Is Compelling J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5483 - 5488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kahaly and W. H. Dillmann Thyroid Hormone Action in the Heart Endocr. Rev., August 1, 2005; 26(5): 704 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zoncu, F. Pigliaru, C. Putzu, L. Pisano, S. Vargiu, M. Deidda, S. Mariotti, and G. Mercuro Cardiac function in borderline hypothyroidism: a study by pulsed wave tissue Doppler imaging Eur. J. Endocrinol., April 1, 2005; 152(4): 527 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ripoli, A. Pingitore, B. Favilli, A. Bottoni, S. Turchi, N. F. Osman, D. De Marchi, M. Lombardi, A. L'Abbate, and G. Iervasi Does subclinical hypothyroidism affect cardiac pump performance?: Evidence from a magnetic resonance imaging study J. Am. Coll. Cardiol., February 1, 2005; 45(3): 439 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kenessey and K. Ojamaa Ligand-mediated decrease of thyroid hormone receptor-{alpha}1 in cardiomyocytes by proteosome-dependent degradation and altered mRNA stability Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H813 - H821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Imaizumi, M. Akahoshi, S. Ichimaru, E. Nakashima, A. Hida, M. Soda, T. Usa, K. Ashizawa, N. Yokoyama, R. Maeda, et al. Risk for Ischemic Heart Disease and All-Cause Mortality in Subclinical Hypothyroidism J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3365 - 3370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gumieniak, T. S. Perlstein, P. N. Hopkins, N. J. Brown, L. J. Murphey, X. Jeunemaitre, N. K. Hollenberg, and G. H. Williams Thyroid Function and Blood Pressure Homeostasis in Euthyroid Subjects J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3455 - 3461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Helfand Screening for Subclinical Thyroid Dysfunction in Nonpregnant Adults: A Summary of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, January 20, 2004; 140(2): 128 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Surks, E. Ortiz, G. H. Daniels, C. T. Sawin, N. F. Col, R. H. Cobin, J. A. Franklyn, J. M. Hershman, K. D. Burman, M. A. Denke, et al. Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management JAMA, January 14, 2004; 291(2): 228 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fazio, E. A. Palmieri, G. Lombardi, and B. Biondi Effects of Thyroid Hormone on the Cardiovascular System Recent Prog. Horm. Res., January 1, 2004; 59(1): 31 - 50. [Abstract] [Full Text]
|
|
|
|
 |
|
 E Toscano, G Pacileo, G Limongelli, M Verrengia, O Di Mita, S Di Maio, M Salerno, E Del Giudice, B Caniello, R Calabro, et al. Subclinical hypothyroidism and Down's syndrome; studies on myocardial structure and function Arch. Dis. Child., November 1, 2003; 88(11): 1005 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Biondi, E. A. Palmieri, G. Lombardi, and S. Fazio Effects of Subclinical Thyroid Dysfunction on the Heart Ann Intern Med, December 3, 2002; 137(11): 904 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Vitale, M. Galderisi, G. A. Lupoli, A. Celentano, I. Pietropaolo, N. Parenti, O. de Divitiis, and G. Lupoli Left Ventricular Myocardial Impairment in Subclinical Hypothyroidism Assessed by a New Ultrasound Tool: Pulsed Tissue Doppler J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4350 - 4355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Caraccio, E. Ferrannini, and F. Monzani Lipoprotein Profile in Subclinical Hypothyroidism: Response to Levothyroxine Replacement, a Randomized Placebo-Controlled Study J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1533 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. McDermott and E. C. Ridgway Subclinical Hypothyroidism Is Mild Thyroid Failure and Should be Treated J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4585 - 4590. [Full Text] [PDF]
|
|
|
|
|
|
J. W. Chu and L. M. Crapo The Treatment of Subclinical Hypothyroidism Is Seldom Necessary J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4591 - 4599. [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Cooper Subclinical Hypothyroidism N. Engl. J. Med., July 26, 2001; 345(4): 260 - 265. [Full Text] [PDF]
|
|
|
|
|
|
F. Monzani, V. Di Bello, N. Caraccio, A. Bertini, D. Giorgi, C. Giusti, and E. Ferrannini Effect of Levothyroxine on Cardiac Function and Structure in Subclinical Hypothyroidism: A Double Blind, Placebo-Controlled Study J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1110 - 1115. [Abstract] [Full Text]
|
|
|
|
|
|
I. Klein and K. Ojamaa Thyroid Hormone and the Cardiovascular System N. Engl. J. Med., February 15, 2001; 344(7): 501 - 509. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Klein and K. Ojamaa Editorial: Thyroid Hormone--Targeting the Heart Endocrinology, January 1, 2001; 142(1): 11 - 12. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
